CI looks worth holding as Evernorth growth, expanding pharmacy services, cheap valuation and shareholder returns support its ...
Phase 1 results confirm investigational drug-candidate G1090N has a favorable safety and tolerability profile, supporting further clinical evaluationCompelling anti-inflammatory activity of G1090N was ...
Shahar Azulay, CEO and cofounder of groundcover is a serial R&D leader. Shahar brings experience in the world of cybersecurity and machine learning having worked as a leader in companies such as Apple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback